BioPharma Resources

Drug Trial Radar · NCT06081920

A Study of IBI363 in Subjects With Advanced Melanoma

A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of IBI363 in Subjects With Advanced Melanoma

Last checked: Nov 19, 2026Latest source record: Jul 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Oct 19, 2023

Primary completion

Oct 19, 2028

Study completion Oct 19, 2028

Sponsor

Sponsor type
Industry
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-lable, multicenter Phase II study to evaluate the safety, tolerability, and efficacy of IBI363 in advanced melanoma patients

Conditions

  • Melanoma

Interventions

  • IBI363Biological

    IBI363 monotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AE(Adverse event)Time frame: 2 years
  2. ORR(Objective response rate)Time frame: 2 years
  3. DoR(duration of response)Time frame: 2 years
  4. PFS (progression free survival)Time frame: 2 years
  5. DCR (disease control rate)Time frame: 2 years
  6. TTR (time to response)Time frame: 2 years
  7. TTP (time to progression)Time frame: 2 years

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Cancer Hospital & Institute, Beijing, China,

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Recruiting

  • The Third people's hospital of Zhengzhou

    Zhengzhou, Henan, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • Nanjing Drum Tower Hospital

    Nanjing, Jiangsu, China · Recruiting

  • The first affiliated hospital of Nanchang university

    Nanchang, Jiangxi, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Recruiting

  • The first hospital of Jilin University

    Changchun, Jilin, China · Recruiting

  • Qilu Hospital of Shandong university

    Jinan, Shandong, China · Recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Recruiting

  • Yunan Cancer Hospital

    Kunming, Yunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.